0,1,2,3,4,5
Table 6.3.5:  Randomised controlled trials comparing salvage radiotherapy combined with androgen,,,,,
Study,n,Risk groups,Median   FU (mo),Regimen,Outcome
GETUG-AFU 16   2019 [1044],369 RT + ADT    374 RT,ISUP grade   < 2/3 89%  ISUP grade    > 4 11%   cN0,112,66 Gy PBRT + 6 mo.   LHRH analogue   66 Gy BPRT,"10-yr.   PFS: RT + ADT, 64%  PFS: RT, 49%  p < 0.0001  MFS: RT + ADT, 75%  MFS: RT, 69%  p = 0.034"
RTOG 9601    2017 [1043],384 RT + ADT    376 RT,"pT2 R1, pT3   cN0",156,64.8 Gy PBRT +   bicalutamide 24 mo.   64.8 Gy PBRT +   placebo,12-yr.   cumulative DM  RT + ADT: 14%  RT + placebo: 23%  p = 0.005  OS  RT + ADT: 76%  RT + placebo: 71%  p = 0.04  DSM  RT + ADT: 5.8%  RT + placebo: 13.4%  p < 0.001
NRG Oncology/  RTOG 0534   SPPORT [1045],574 SRT +   PBRT + ADT  578 SRT +   ADT  564 SRT,pT2 or pT3  ISUP < 5  Pre SRT    PSA: 0.1-2.0,survivors:  8.2 years,64.8–0.2 Gy PBRT  64.8–70.2 Gy PBRT  6 mo. LHRH analogue  64.8–70.2 Gy PBRT +   45 Gy PLNRT  6 mo. LHRH analogue,5-yr. FFP (primary   endpoint)  70.9% Group 1  81.3% Group 2  87.4% Group 3  Comparisons :  G 3 vs. G 1:  p < 0.0001  G 2 vs. G 1  p < 0.0001  G 3 vs. G 2  p < 0.0027
